Author

Luping Jiang

Observed name: Jiang, Luping

Institutions: Changsha Central Hospital, University of South China

Observed institutions: Changsha Central Hospital, University of South China

OpenAlex ID: A5114042002

Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial

2025 · Javed Butler, Ciaran J McMullan, et al. · The Lancet · 92

Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials

2025 · Faiez Zannad, Christopher M O'Connor, et al. · The Lancet · 50

Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome

2023 · Shenghua Zhou, Yichao Xiao, et al. · JAMA Network Open · 10

miR-19a-3p affected ox-LDL-induced SDC-1/TGF-β1/Smad3 pathway in atherosclerosis

2023 · Qiao Jin, Yiming Deng, et al. · Cellular and Molecular Biology · 7

The effect of vericiguat on sudden cardiac death: insights from the VICTOR trial

2026 · Francesco Fioretti, Faiez Zannad, et al. · European Journal of Heart Failure · 1

Targeting ADAMTS1/HDAC6 alleviates TGF-β1/SMAD2-associated cardiac fibrosis in cardiac fibrosis post-myocardial infarction

2026 · Qiao Jin, Chun Chen, et al. · Cell Biology and Toxicology · 1

Works count: 8

Citation count: 161

H-index: 4

I10-index: 3